Drug Profile
Influenza A virus DNA vaccine H1N1 - Fresh Tracks Therapeutics
Alternative Names: Influenza A (H1N1) DNA vaccine - Fresh Tracks Therapeutics; Pandemic influenza plasmid DNA vaccine H1N1- Fresh Tracks Therapeutics; Swine flu DNA vaccine - Fresh Tracks Therapeutics; Vaxfectin®-formulated plasmid DNA vaccine H1N1 - Fresh Tracks TherapeuticsLatest Information Update: 25 Sep 2023
Price :
$50
*
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Influenza A virus H1N1 subtype
Most Recent Events
- 19 Sep 2023 Discontinued - Phase-I for Influenza A virus H1N1 subtype (Prevention) in USA (IM)
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary